Compare IPAR & VKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IPAR | VKTX |
|---|---|---|
| Founded | 1982 | 2012 |
| Country | United States | United States |
| Employees | 662 | N/A |
| Industry | Package Goods/Cosmetics | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 4.4B |
| IPO Year | 1995 | 2014 |
| Metric | IPAR | VKTX |
|---|---|---|
| Price | $119.75 | $35.39 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 7 |
| Target Price | ★ $116.60 | $95.86 |
| AVG Volume (30 Days) | 343.8K | ★ 3.0M |
| Earning Date | 05-05-2026 | 04-29-2026 |
| Dividend Yield | ★ 3.54% | N/A |
| EPS Growth | ★ 2.34 | N/A |
| EPS | ★ 1.35 | N/A |
| Revenue | ★ $1,317,700,000.00 | N/A |
| Revenue This Year | $3.86 | N/A |
| Revenue Next Year | $7.89 | N/A |
| P/E Ratio | $90.53 | ★ N/A |
| Revenue Growth | ★ 21.26 | N/A |
| 52 Week Low | $77.21 | $22.96 |
| 52 Week High | $128.62 | $43.15 |
| Indicator | IPAR | VKTX |
|---|---|---|
| Relative Strength Index (RSI) | 54.84 | 49.62 |
| Support Level | $88.45 | $28.50 |
| Resistance Level | $124.33 | $36.77 |
| Average True Range (ATR) | 3.89 | 2.02 |
| MACD | -0.69 | -0.51 |
| Stochastic Oscillator | 24.29 | 13.33 |
Interparfums Inc operates in the fragrance business and produces and distributes a wide array of prestige fragrance and fragrance-related products. It sells its product under the brand which includes Boucheron, Coach, Jimmy Choo, Karl Lagerfeld, Kate Spade, Lacoste, Lanvin, Moncler, Montblanc, Rochas and Van Cleef & Arpels. The company operates in two operating segments namely European based operations, SA, and United States based operations. The group sells its products to department stores, perfumeries, specialty stores, and domestic and international wholesalers and distributors.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, and VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype-selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.